BOULDER, Colo., Sept. 14 /PRNewswire-FirstCall/ -- Array BioPharma Inc. (Nasdaq: ARRY - News) today announced that it received a $3 million payment from AstraZeneca (NYSE: AZN - News) for achieving a Phase 2 milestone for AZD6244 (ARRY-142886). The payment was triggered upon dosing the first patient in a Phase 2 trial. AZD6244 (ARRY-142886) is a selective MEK inhibitor that was in-licensed by AstraZeneca from Array in December 2003.
